

# Jean-Yves Scoazec

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7949310/publications.pdf>

Version: 2024-02-01

69  
papers

4,261  
citations

201674

27  
h-index

114465

63  
g-index

71  
all docs

71  
docs citations

71  
times ranked

6157  
citing authors

#	ARTICLE	IF	CITATIONS
1	A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 518-525.	7.0	7
2	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2022, 40, 318-334.e9.	16.8	97
3	The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. <i>Cancer Discovery</i> , 2022, 12, 1266-1281.	9.4	67
4	<i>NF1</i>-Associated Inflammatory Polyp of the Colon: First Report of a Sporadic Case. <i>International Journal of Surgical Pathology</i> , 2022, 30, 823-827.	0.8	1
5	Cancer Induces a Stress Ileopathy Depending on $\beta^2$ -Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. <i>Cancer Discovery</i> , 2022, 12, 1128-1151.	9.4	44
6	Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. <i>Nature Communications</i> , 2022, 13, 1985.	12.8	14
7	Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival. <i>Cancers</i> , 2022, 14, 2225.	3.7	1
8	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived eXplants. <i>JCI Insight</i> , 2022, . .	5.0	5
9	Neuropilin-1 cooperates with PD-1 in CD8+ T $\beta$ cells predicting outcomes in melanoma patients treated with anti-PD1. <i>IScience</i> , 2022, 25, 104353.	4.1	3
10	Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. <i>Cancers</i> , 2022, 14, 2937.	3.7	9
11	Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100611.	1.7	0
12	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. <i>Neuroendocrinology</i> , 2021, 111, 883-894.	2.5	54
13	Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 885-891.	2.8	9
14	Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. <i>Cell Death and Differentiation</i> , 2021, 28, 1532-1547.	11.2	11
15	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcS $\text{\textcircled{A}}$ -ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. <i>European Journal of Cancer</i> , 2021, 150, 53-62.	2.8	33
16	Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer. <i>Cancer Research</i> , 2021, 81, 448-448.	0.9	3
17	FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. <i>Digestive and Liver Disease</i> , 2021, 53, 824-829.	0.9	9
18	Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. <i>European Journal of Cancer</i> , 2021, 151, 106-114.	2.8	18

#	ARTICLE	IF	CITATIONS
19	Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Étude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. <i>European Journal of Cancer</i> , 2021, 152, 100-115.	2.8	9
20	PAX3-NCOA1 alveolar rhabdomyosarcoma of the tongue: A rare entity with challenging diagnosis and management. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29288.	1.5	2
21	PD-L1 regulation revisited: impact on immunotherapeutic strategies. <i>Trends in Molecular Medicine</i> , 2021, 27, 868-881.	6.7	30
22	Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. <i>Nature Genetics</i> , 2021, 53, 1553-1563.	21.4	71
23	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. <i>Cancers</i> , 2021, 13, 5366.	3.7	17
24	Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours. <i>British Journal of Cancer</i> , 2020, 122, 564-568.	6.4	8
25	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	3.7	44
26	Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients. <i>Cancers</i> , 2020, 12, 1871.	3.7	14
27	CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. <i>Cell Reports Medicine</i> , 2020, 1, 100127.	6.5	70
28	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. <i>Cell Reports</i> , 2020, 33, 108421.	6.4	77
29	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	5.4	16
30	DNA FISH Diagnostic Assay on Cytological Samples of Thyroid Follicular Neoplasms. <i>Cancers</i> , 2020, 12, 2529.	3.7	3
31	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	2.8	53
32	Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France). <i>Cancers</i> , 2020, 12, 955.	3.7	16
33	Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. <i>Nature Communications</i> , 2020, 11, 1884.	12.8	62
34	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	30.7	118
35	Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment. <i>Cells</i> , 2019, 8, 714.	4.1	97
36	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. <i>Cancers</i> , 2019, 11, 1271.	3.7	27

#	ARTICLE	IF	CITATIONS
37	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. <i>Histopathology</i> , 2019, 75, 312-319.	2.9	15
38	Circulating Tumor Cell Detection in Lung Cancer: But to What End?. <i>Cancers</i> , 2019, 11, 262.	3.7	19
39	Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?. <i>Cancers</i> , 2019, 11, 283.	3.7	86
40	Hepatocellular adenomas: one step beyond. <i>Gut</i> , 2019, 68, 1140-1142.	12.1	2
41	Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer?. <i>Journal of Clinical Medicine</i> , 2019, 8, 414.	2.4	26
42	Lung Cancer Screening, towards a Multidimensional Approach: Why and How?. <i>Cancers</i> , 2019, 11, 212.	3.7	31
43	The Desire to Better Understand Older Adults with Solid Tumors to Improve Management: Assessment and Guided Interventions—The French PACA EST Cohort Experience. <i>Cancers</i> , 2019, 11, 192.	3.7	13
44	The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. <i>Cancers</i> , 2019, 11, 250.	3.7	2
45	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. <i>Nature Communications</i> , 2019, 10, 5713.	12.8	70
46	Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. <i>Nature Cell Biology</i> , 2018, 20, 296-306.	10.3	88
47	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018, 92, 1-10.	2.8	14
48	Arterial thrombosis and anti-PD-1 blockade. <i>European Journal of Cancer</i> , 2018, 91, 164-166.	2.8	26
49	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase—mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	2.8	28
50	Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 116-124.	0.6	16
51	Translational control of tumor immune escape via the eIF4F—STAT1—PD-L1 axis in melanoma. <i>Nature Medicine</i> , 2018, 24, 1877-1886.	30.7	180
52	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. <i>European Journal of Cancer</i> , 2018, 103, 108-119.	2.8	18
53	Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. <i>Cancers</i> , 2018, 10, 326.	3.7	23
54	Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?. <i>Cancers</i> , 2018, 10, 70.	3.7	21

#	ARTICLE	IF	CITATIONS
55	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786.	5.5	739
56	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 153-162.	2.0	17
57	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12
58	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2017, 49, 568-571.	0.9	3
59	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	1.3	290
60	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	2.8	120
61	Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. <i>Neuroendocrinology</i> , 2017, 105, 26-34.	2.5	11
62	ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients. <i>Cancers</i> , 2017, 9, 106.	3.7	22
63	ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. <i>Cancers</i> , 2017, 9, 107.	3.7	47
64	Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. <i>Cancers</i> , 2017, 9, 154.	3.7	31
65	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4080-4088.	3.6	72
66	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	3.7	354
67	Discriminating Gene Expression Signature of Radiation-Induced Thyroid Tumors after Either External Exposure or Internal Contamination. <i>Genes</i> , 2012, 3, 19-34.	2.4	8
68	Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. <i>Hepatology</i> , 2006, 43, 515-524.	7.3	733
69	Diagnostic Challenges and Pitfalls of Mammary Pleomorphic Adenoma Illustrated by a Case Report. <i>International Journal of Surgical Pathology</i> , 0, , 106689692211025.	0.8	0